0001179110-18-002466.txt : 20180221
0001179110-18-002466.hdr.sgml : 20180221
20180221160908
ACCESSION NUMBER: 0001179110-18-002466
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180216
FILED AS OF DATE: 20180221
DATE AS OF CHANGE: 20180221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Quirk Gerald E
CENTRAL INDEX KEY: 0001479603
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37813
FILM NUMBER: 18628471
MAIL ADDRESS:
STREET 1: C/O SYROS PHARMACEUTICALS, INC.
STREET 2: 620 MEMORIAL DRIVE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Syros Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001556263
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 453772460
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 620 MEMORIAL DRIVE
STREET 2: SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-744-1340
MAIL ADDRESS:
STREET 1: 620 MEMORIAL DRIVE
STREET 2: SUITE 300
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: LS22, Inc.
DATE OF NAME CHANGE: 20120815
4
1
edgar.xml
FORM 4 -
X0306
4
2018-02-16
0
0001556263
Syros Pharmaceuticals, Inc.
SYRS
0001479603
Quirk Gerald E
C/O SYROS PHARMACEUTICALS, INC.
620 MEMORIAL DRIVE, SUITE 300
CAMBRIDGE
MA
02139
0
1
0
0
Chief Legal Officer
Stock Option (right to buy)
10.09
2018-02-16
4
A
0
75000
0
A
2028-02-15
Common Stock
75000
75000
D
Stock Option (right to buy)
13.30
2018-02-16
4
A
0
11666
0
A
2018-02-16
2026-09-26
Common Stock
11666
11666
D
This option becomes exercisable as to 25% of the shares underlying the award on February 28, 2019, with the remainder vesting in equal monthly installments of 2.0833% of the shares underlying the award at the end of each successive month thereafter.
On September 27, 2016, the Reporting Person was granted an option to purchase 35,000 shares of common stock. The option vests upon the achievement of performance-based criteria as determined by the Issuer's Board of Directors. On February 16, 2018, it was determined that certain of the performance criteria were met, resulting in vesting of the option as to 11,666 shares.
/s/ Gerald E. Quirk
2018-02-20